Blocking TIGIT/CD155 signalling reverses CD8⁺ T cell exhaustion and enhances the antitumor activity in cervical cancer.

ABSTRACT:

Objective

TIGIT/CD155 has attracted widespread attention as a new immune checkpoint and a potential target for cancer immunotherapy. In our study, we evaluated the role of TIGIT/CD155 checkpoints in the progression of cervical cancer.

Methods

The expression of CD155 and TIGIT in cervical cancer tissues was detected using flow cytometry, immunohistochemistry (IHC) and gene expression profiling. In vivo and in vitro experiments have proven that blocking TIGIT/CD155 restores the ability of CD8⁺ T cells to produce cytokines. Changes in the NF-κB and ERK pathways were detected using western blotting (WB) after blocking TIGIT/CD155 signalling.

Results

TIGIT expression was elevated in patients with cervical cancer. High TIGIT expression in CD8⁺ T lympho

SUBMITTER: Liu L 

PROVIDER: S-EPMC9210727 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature